Medifast (MED) Fundamental Analysis: Revenue, Earnings & Valuation

9.54 / 10

Outperform

Fundamental assessment rates MED at 9.5/10, earning an Outperform label. Key strengths are PB‑ROE, Asset‑MV and Revenue‑MV, each with strong positive weights, while EPS growth metrics are weak. Overall fund‑flow score is 9.54, reinforcing the stock’s solid valuation foundation.

Analysis Checks(3/10)

Revenue-MV

Value1.17

Score2/3

Weight25.32%

1M Return3.24%

Net cash flow from operating activities per share (YoY growth rate %)

Value-72.10

Score0/3

Weight-16.83%

1M Return-3.08%

PB-ROE

Value-0.59

Score3/3

Weight68.47%

1M Return8.31%

Basic earnings per share (YoY growth rate %)

Value-994.74

Score0/3

Weight-10.16%

1M Return-1.82%

Total profit (YoY growth rate %)

Value-248.90

Score0/3

Weight-17.80%

1M Return-3.20%

Net cash flow from operating activities (YoY growth rate %)

Value-71.96

Score0/3

Weight-16.46%

1M Return-2.92%

Cash-UP

Value-0.15

Score1/3

Weight4.65%

1M Return0.66%

Diluted earnings per share (YoY growth rate %)

Value-994.74

Score0/3

Weight-9.75%

1M Return-1.72%

Asset-MV

Value-0.55

Score3/3

Weight82.15%

1M Return9.13%

Cash-MV

Value0.02

Score0/3

Weight-9.58%

1M Return-1.72%

Is MED undervalued or overvalued?

MED scores 9.54/10 on fundamentals and holds a Discounted valuation at present. Backed by its -9.13% ROE, -4.84% net margin, -5.74 P/E ratio, 0.54 P/B ratio, and -994.74% earnings growth, these metrics solidify its Outperform investment rating.